Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Assura plc (LSE:AGR) announced on Wednesday that four senior executives exercised their 2022 Performance Share Plan (PSP) awards on July 22, with varying approaches to their resulting shareholdings.
CEO Jonathan Murphy exercised 344,426 shares, selling 161,880 to cover tax obligations and retaining the remaining 182,546 shares. CFO Jayne Cottam followed a similar pattern, exercising 200,490 shares, selling 94,230 for tax purposes, and keeping 106,260 shares.
In contrast, General Counsel Orla Ball (NYSE:BALL) and Group Development Director Rob James sold their entire allocations after tax deductions. Ball exercised 62,964 shares but sold all holdings (29,593 for tax obligations and the remaining 33,371), while James exercised 80,135 shares and similarly sold his full allocation (37,663 for tax and 42,472 additional shares).
The transactions occurred at a price of £0.5025 per share, according to the company statement.
Following these transactions, Murphy’s total shareholding increased to 3,517,763 shares from 3,335,217, while Cottam’s holdings rose to 1,066,622 from 960,362. Ball’s shareholding remained unchanged at 47,060, as did James’s at 37,667.
The company noted that both Murphy and Cottam transferred their newly acquired shares to their spouses, with their total beneficial holdings remaining unchanged.
The Remuneration Committee had previously approved the sale of sufficient shares to cover tax liabilities, as well as permitting Ball and James to sell their remaining restricted shares in full.
This information was disclosed in accordance with the Market Abuse Regulation, based on a regulatory news statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.